| Document Date: 2015-04-09 19:36:25
Open Document File Size: 866,86 KBShare Result on Facebook
City MELBOURNE / / Company Fidelis Design Associates / Novartis / Merck and Co. Inc. / CSL Group / Consolidate Holdings / CSL Limited / FSC / Shareholder Information Share Registry Computershare Investor Services Pty Limited / / Continent Europe / / Country New Zealand / Japan / United States / Australia / United Kingdom / China / / Currency NZD / AUD / USD / / Event Security Buyback / FDA Phase / Dividend Issuance / M&A / / Facility NATIONAL TENNIS CENTRE / D pipeline / / IndustryTerm haemophilia products / financial management / wound healing products / technology add-on payment / albumin manufacturing facilities / manufacturing / scaled manufacturing facilities / manufacturing plants / / MedicalCondition haemophilia / chronic inflammatory demyelinating polyneuropathy / HAE / hereditary angioedema / severe influenza / influenza / Primary Immune Deficiency / haemophilia B / / MedicalTreatment surgery / / NaturalFeature Information Share Registry Computershare Investor Services Pty Limited Yarra Falls / / Organization Medicare / US Food and Drug Administration / Investor Centre / / Person John Shine / / / Position sponsoring broker / broker / AO Chairman / Registered Head Office / Chairman / Professor / / Product Gardasil / Kcentra® / CSL654 / CSL112 / / Technology antibodies / / URL www.investorcentre.com / http /
SocialTag |
CSL Limited Half Year Report Dividend to Shareholders An interim unfranked dividend of US$0.58